Dr Reddy's Labs

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE089A01031
  • NSEID: DRREDDY
  • BSEID: 500124
INR
1,390.50
-7.5 (-0.54%)
BSENSE

Nov 20

BSE+NSE Vol: 8.53 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,390.50",
    "chg": -7.5,
    "chgp": "-0.54%",
    "dir": -1,
    "prev_price": "1,398.00",
    "mcapval": "116,687.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE089A01031",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "8.53 lacs",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Dr Reddys Laboratories Gains 0.98%: 2 Key Technical Signals Driving Momentum",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/dr-reddys-laboratories-gains-098-2-key-technical-signals-driving-momentum-4270624",
        "imagepath": "",
        "date": "2026-11-21 16:01:51",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>16 Nov:</strong> Stock opens at Rs.1,380.00 with mild gains</p>\n                    <p><strong>18 Nov:</strong> Golden Cross formation signals potential bullish breakout</p>\n                    <p><strong>19 Nov:</strong> Technical momentum upgraded to bullish, stock nears 52-week high</p>\n                    <p><strong>20 Nov:</strong> Week closes at Rs.1,390.50, up 0.98% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,380.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-va..."
      },
      {
        "title": "P/E at 41.7 vs Industry's 39.5: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-market-dynamics-4268988",
        "imagepath": "",
        "date": "2026-11-20 09:20:53",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Premium Reflects Confidence Amid Sector Norms</strong></p>\n                <p>The current P/E of 41.71 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands slightly above the Pharmaceuticals &amp; Biotechnology industry average of 39.53. This premium, though not excessive, suggests that the market is pricing in expectations of steady earnings growth or superior operational performance relative to peers. The valuation premium is consistent with the company’s mid-cap status and its position near a 52-week high, just 1.38% shy of Rs 1414.4.</p>\n                <p>However, the premium also invites scrutiny — <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd Technical Momentum Shifts Signal Bullish Outlook",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/dr-reddys-laboratories-ltd-technical-momentum-shifts-signal-bullish-outlook-4267490",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/DrReddysLaborat_technicaldot_4267490.png",
        "date": "2026-11-19 08:03:32",
        "description": "Dr Reddys Laboratories Ltd has witnessed a notable shift in its technical momentum, with key indicators signalling an upgrade from a mildly bullish to a bullish trend. This change reflects improving price dynamics and growing investor confidence in the mid-cap pharmaceutical giant, supported by robust moving averages and positive MACD and Bollinger Bands readings."
      },
      {
        "title": "Golden Cross Confirmed: Do Dr Reddys Laboratories Ltd's Other Technical Indicators Agree?",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/dr-reddys-laboratories-ltd-forms-golden-cross-signalling-potential-bullish-breakout-4267339",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/DrReddysLaborat_goldencross_4267339.png",
        "date": "2026-11-18 18:00:23",
        "description": "The 50-day moving average has crossed above the 200-day moving average for Dr Reddys Laboratories Ltd, signalling a golden cross on 18 Nov 2026. While this technical event often suggests a shift towards bullish momentum, the broader technical and fundamental context must be examined to assess the signal's reliability."
      },
      {
        "title": "P/E at 41.38 vs Industry's 39.31: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4266492",
        "imagepath": "",
        "date": "2026-11-18 09:20:45",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Index Membership and Market Capitalisation Impact</strong></p>\n                <p>As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in shaping the benchmark's pharmaceutical and biotechnology representation. The company's market capitalisation stands at ₹1,15,768.64 crores, categorising it as a mid-cap stock within the broader index framework. This positioning ensures that Dr Reddys commands considerable attention from index funds and institutional investors tracking the Nifty 50, thereby influencing liquidity and trading volumes.</p>\n                <p>Its proximity to the 52-week high—just 2.2% shy of ₹1,414.4—signals sustained investor confidence, despite a minor day-on-day decline of 0.07%. The stock opened at ₹1,384 and maintained this leve..."
      },
      {
        "title": "P/E at 41.17 vs Industry's 39.33: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-market-dynamics-4264900",
        "imagepath": "",
        "date": "2026-11-17 09:21:24",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Premium Reflecting Market Confidence?</strong></p>\n                <p>The current P/E of 41.17 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> is marginally higher than the industry average of 39.33, indicating a valuation premium of roughly 4.7%. This premium suggests that investors are willing to pay slightly more for the stock relative to its peers in Pharmaceuticals & Biotechnology. Such a premium can be interpreted as a reflection of the company’s perceived earnings quality, growth prospects, or market positioning. However, the premium is not excessive, signalling a balanced valuation stance rather than an overheated one. <a href=\"https://www.marketsmojo.com/stocks-analysis/dr..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd is Rated Hold",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/dr-reddys-laboratories-ltd-is-rated-hold-4262404",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/DrReddysLaborat_mojoScore_4262404.png",
        "date": "2026-11-15 10:10:29",
        "description": "Dr Reddys Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 03 Nov 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 15 November 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "P/E at 41.35 vs Industry's 39.79: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4260304",
        "imagepath": "",
        "date": "2026-11-13 09:20:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Premium Reflecting Sector Confidence</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\" target=\"_blank\">Dr Reddys Laboratories Ltd</a> trades at a P/E of 41.35, slightly above the Pharmaceuticals &amp; Biotechnology industry average of 39.79. This premium, though not excessive, suggests the market assigns a somewhat higher growth or quality expectation to the company relative to its peers. The sector’s average P/E reflects a broad range of valuations, with some stocks trading at steep discounts and others commanding significant premiums. The current valuation implies that investors are willing to pay a 3.9% premium for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-..."
      },
      {
        "title": "Dr Reddys Laboratories Gains 1.56%: 2 Key Factors Driving the Mild Bullish Shift",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/dr-reddys-laboratories-gains-156-2-key-factors-driving-the-mild-bullish-shift-4255581",
        "imagepath": "",
        "date": "2026-11-07 16:02:14",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Nov:</strong> Stock opens at ₹1,340.25, declines 0.74% amid Sensex rally</p>\n                    <p><strong>3 Nov:</strong> Mojo Grade upgraded to Hold; stock surges 2.22% to ₹1,370.00</p>\n                    <p><strong>4 Nov:</strong> Technical momentum shifts signal mild bullish outlook; stock edges up 0.15%</p>\n                    <p><strong>5 Nov:</strong> Stock dips 0.82% despite Sensex gaining 2.05%</p>\n                    <p><strong>6 Nov:</strong> Stock rebounds 0.76% to close at ₹1,371.20</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">₹1,350.20<..."
      }
    ],
    "total": 232,
    "sid": "734514",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015",
      "datetime": "14-Nov-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "11-Nov-2026",
      "details": "Copies of newspaper publication",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "10-Nov-2026",
      "details": "Intimation of Analyst meet",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 26",
          "dt": "2026-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015

14-Nov-2026 | Source : BSE

Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015

Announcement under Regulation 30 (LODR)-Newspaper Publication

11-Nov-2026 | Source : BSE

Copies of newspaper publication

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

10-Nov-2026 | Source : BSE

Intimation of Analyst meet

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Dr Reddys Laboratories Ltd has declared 800% dividend, ex-date: 10 Jul 26

stock-summary
SPLITS

Dr Reddys Laboratories Ltd has announced 1:5 stock split, ex-date: 28 Oct 24

stock-summary
BONUS

Dr Reddys Laboratories Ltd has announced 1:1 bonus issue, ex-date: 28 Aug 06

stock-summary
RIGHTS

No Rights history available